• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.

作者信息

Wang Ying, Hu Mengke, Yang Haiyan

机构信息

Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China.

Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China.

出版信息

J Hepatol. 2023 Jan;78(1):e28-e31. doi: 10.1016/j.jhep.2022.09.015. Epub 2022 Sep 27.

DOI:10.1016/j.jhep.2022.09.015
PMID:36179997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9513401/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbf/9513401/1ba27b1da4e3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbf/9513401/1ba27b1da4e3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbf/9513401/1ba27b1da4e3/gr1_lrg.jpg

相似文献

1
Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
J Hepatol. 2023 Jan;78(1):e28-e31. doi: 10.1016/j.jhep.2022.09.015. Epub 2022 Sep 27.
2
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.比较肝硬化合并 COVID-19 患者与单纯肝硬化患者和单纯 COVID-19 患者的死亡率风险：多中心匹配队列研究。
Gut. 2021 Mar;70(3):531-536. doi: 10.1136/gutjnl-2020-322118. Epub 2020 Jul 13.
3
Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies.COVID-19 与肝硬化的临床结局：观察性研究的系统评价和荟萃分析。
BMJ Open Gastroenterol. 2021 Oct;8(1). doi: 10.1136/bmjgast-2021-000739.
4
Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study.慢性丙型肝炎合并和不合并肝硬化以及 COVID-19 感染患者的生存和结局：一项多中心回顾性研究。
World J Gastroenterol. 2021 Nov 14;27(42):7362-7375. doi: 10.3748/wjg.v27.i42.7362.
5
More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.加大力度探索肝硬化与新冠肺炎死亡率之间的关联，以及非酒精性脂肪性肝病与重症新冠肺炎之间的关联。
J Hepatol. 2023 May;78(5):e178-e180. doi: 10.1016/j.jhep.2022.11.024. Epub 2022 Dec 9.
6
High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study.高 Child-Pugh 和 CRUB65 评分可预测 COVID-19 失代偿性肝硬化患者的死亡率：一项 23 中心回顾性研究。
Virulence. 2021 Dec;12(1):1199-1208. doi: 10.1080/21505594.2021.1909894.
7
Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic.美国慢性肝病和肝硬化患者的死亡率趋势：新冠疫情之前和期间的情况。
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2664-2666.e2. doi: 10.1016/j.cgh.2021.07.009. Epub 2021 Jul 10.
8
Letter to the editor: Could COVID-19 vaccination reduce postinfection mortality in most patients with cirrhosis?致编辑的信：新冠病毒疫苗接种能否降低大多数肝硬化患者感染后的死亡率？
Hepatology. 2023 Feb 1;77(2):E32. doi: 10.1002/hep.32751. Epub 2022 Sep 3.
9
COVID-19 in patients with cirrhosis: understanding adverse impact.
Gut. 2021 Jul;70(7):1409. doi: 10.1136/gutjnl-2020-322561. Epub 2020 Aug 21.
10
Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation.大流行对急性肝硬化失代偿患者入院、发病和早期死亡率的负面影响。
BMJ Open Gastroenterol. 2023 Jan;10(1). doi: 10.1136/bmjgast-2022-001071.

引用本文的文献

1
Acute Variceal Bleeding During the SARS-CoV-2 Pandemic: A National Multicenter Observational Study.2019冠状病毒病大流行期间的急性静脉曲张出血：一项全国多中心观察性研究
J Clin Med. 2025 Aug 31;14(17):6166. doi: 10.3390/jcm14176166.
2
Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.胆固醇和降胆固醇药物在 COVID-19 中的作用——一个悬而未决的问题。
Int J Mol Sci. 2024 Sep 29;25(19):10489. doi: 10.3390/ijms251910489.
3
Factors Associated with All-Cause 30-Day Mortality in Indonesian Inpatient COVID-19 Patients at Cipto Mangunkusumo National General Hospital.

本文引用的文献

1
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.COVID-19 对肝脏的影响以及对慢性肝病、肝胆癌和肝移植患者的治疗影响：EASL 最新立场文件。
J Hepatol. 2022 Oct;77(4):1161-1197. doi: 10.1016/j.jhep.2022.07.008. Epub 2022 Jul 20.
2
Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry.慢性使用皮质类固醇和钙调磷酸酶抑制剂对 COVID-19 临床结局的影响：全国登记分析。
Int J Infect Dis. 2022 Mar;116:51-58. doi: 10.1016/j.ijid.2021.12.327. Epub 2021 Dec 28.
3
雅加达中央医院（Cipto Mangunkusumo National General Hospital）印度尼西亚住院COVID-19患者全因30天死亡率的相关因素
J Clin Med. 2024 May 20;13(10):2998. doi: 10.3390/jcm13102998.
4
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?2023 年关于 COVID-19、可能的肝脏途径和酒精滥用，我们了解多少？
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
5
A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity.消化性溃疡疾病与新型冠状病毒肺炎严重程度关联的Meta分析
Vaccines (Basel). 2023 Jun 11;11(6):1087. doi: 10.3390/vaccines11061087.
6
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.新型冠状病毒肺炎与代谢相关脂肪性肝病的关系：当前证据概述。
Viruses. 2023 Apr 27;15(5):1072. doi: 10.3390/v15051072.
7
COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes.COVID-19 引起的转氨血症和高胆红素血症：表现和结局。
World J Gastroenterol. 2023 Feb 21;29(7):1123-1130. doi: 10.3748/wjg.v29.i7.1123.
8
More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.加大力度探索肝硬化与新冠肺炎死亡率之间的关联，以及非酒精性脂肪性肝病与重症新冠肺炎之间的关联。
J Hepatol. 2023 May;78(5):e178-e180. doi: 10.1016/j.jhep.2022.11.024. Epub 2022 Dec 9.
Risk Factors for Death Among Hospitalized Patients Aged 21-64 Years Diagnosed with COVID-19-New York City, March 13-April 9, 2020.
21-64 岁因 COVID-19 住院患者的死亡危险因素分析-纽约市，2020 年 3 月 13 日-4 月 9 日。
J Racial Ethn Health Disparities. 2022 Aug;9(4):1584-1599. doi: 10.1007/s40615-021-01098-1. Epub 2021 Aug 9.
4
Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study.新型冠状病毒感染、住院和死亡的风险因素：一项基于人群的队列研究。
J Clin Med. 2021 Jun 13;10(12):2608. doi: 10.3390/jcm10122608.
5
Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.是否受到保护，这就是问题所在——关于非酒精性脂肪性肝病患者和肝移植受者对新冠病毒疫苗反应的首批数据。
J Hepatol. 2021 Aug;75(2):265-266. doi: 10.1016/j.jhep.2021.05.007. Epub 2021 May 25.
6
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.EASL 立场文件：关于在慢性肝病、肝胆癌和肝移植受者中使用 COVID-19 疫苗的建议。
J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6.
7
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.丙型肝炎病毒（HCV）相关肝硬化患者接受直接抗病毒药物（DAA）治疗后的临床结局取决于疾病的严重程度。
J Hepatol. 2021 May;74(5):1053-1063. doi: 10.1016/j.jhep.2020.11.021. Epub 2020 Nov 23.
8
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.慢性肝病患者感染 SARS-CoV-2 后的结局：一项国际注册研究。
J Hepatol. 2021 Mar;74(3):567-577. doi: 10.1016/j.jhep.2020.09.024. Epub 2020 Oct 6.
9
MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis.MAIT 细胞在肝功能失代偿的肝硬化患者腹水中富集且功能活跃。
Hepatology. 2020 Oct;72(4):1378-1393. doi: 10.1002/hep.31153. Epub 2020 Oct 13.
10
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.评估卫生保健干预措施的研究的系统评价和Meta分析报告的PRISMA声明：解释与详述。
PLoS Med. 2009 Jul 21;6(7):e1000100. doi: 10.1371/journal.pmed.1000100.